RxDoctor Payments Data

Christopher McGrath, MD

Pulmonary Disease · Philadelphia, PANPI 1811316672

Payments from drug & device makers

$548in general payments, 2019–2025

Across 24 payments — averaging $22.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$199
  • AstraZeneca$75
  • Olympus Corporation Of The Americas$56
  • Abbott$52
  • Sanofi$40
  • Nalu Medical, Inc.$30
  • plus $95 from 4 others

What the payments were for

  • Food & beverage$50792%
  • Education$428%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$548 in reported general payments places this provider in the 35th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$58,100
Medicare patients
205
Services billed
497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter145$107,464
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$29,242
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr43$22,084
Stiolto RespimatTiotropium Br/Olodaterol Hcl33$19,704
Incruse ElliptaUmeclidinium Bromide31$13,609
Spiriva RespimatTiotropium Bromide18$13,243
EliquisApixaban20$12,421
Breo ElliptaFluticasone/Vilanterol26$10,433
DuleraMometasone/Formoterol12$6,617
Albuterol Sulfate HfaAlbuterol Sulfate161$6,371
Combivent RespimatIpratropium/Albuterol Sulfate13$6,238
Arnuity ElliptaFluticasone Furoate14$4,871
Varenicline Tartrate13$3,755
Roflumilast28$2,859
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$2,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta$199$158,461259 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat$25$39,18564 claims
AstraZenecaBreztri Aerosphere$75$29,24230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →